menu
    • menu
    [{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Travere Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Sparsentan","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Renalys Pharma","amount2":0.12,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0.12,"dosageForm":"Tablet, Film Coated","sponsorNew":"Renalys Pharma \/ Renalys Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Renalys Pharma \/ Renalys Pharma"},{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sparsentan","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Renalys Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Renalys Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Renalys Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sparsentan","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Renalys Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Renalys Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Renalys Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Catalys Pacific","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Small molecule","year":"2024","type":"Series A Financing","leadProduct":"Sparsentan","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Renalys Pharma","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Renalys Pharma \/ Catalys Pacific","highestDevelopmentStatusID":"12","companyTruncated":"Renalys Pharma \/ Catalys Pacific"},{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sparsentan","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Renalys Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Renalys Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Renalys Pharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Renalys Pharma

    Menu

    Renalys Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Renalys Pharma

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Renalys Pharma

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sparsentan

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Renalys Pharma Doses First Patient in Phase III Trial of Sparsentan for IgA Nephropathy

                            Details : RE-021 (sparsentan) is an oral drug designed to selectively target two critical pathways - endothelin-1 and angiotensin II. It is approved for the treatment of IgA Nephropathy.

                            Brand Name : RE-021

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 18, 2024

                            Lead Product(s) : Sparsentan

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Renalys Pharma

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Renalys Pharma

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sparsentan

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Catalys Pacific

                            Deal Size : $38.8 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Renalys Pharma Closes ¥60Bn Financing to Advance Kidney Disease Treatments in Asia

                            Details : The financing will enable Renalys Pharma to complete its Phase III clinical trial for RE-021 (sparsentan), a promising treatment for IgA nephropathy, in Japan.

                            Brand Name : RE-021

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 17, 2024

                            Lead Product(s) : Sparsentan

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Catalys Pacific

                            Deal Size : $38.8 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Renalys Pharma

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Renalys Pharma

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sparsentan

                            Therapeutic Area : Nephrology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Renalys Submits IND Application for Sparsentan Phase III Trial in Japan

                            Details : Filspari (sparsentan) is a once-daily oral medication targeting critical pathways in IgAN, approved for the treatment of IgA nephropathy.

                            Brand Name : Filspari

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 07, 2024

                            Lead Product(s) : Sparsentan

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Renalys Pharma

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Renalys Pharma

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sparsentan

                            Therapeutic Area : Nephrology

                            Study Phase : Approved

                            Recipient : Travere Therapeutics

                            Deal Size : $120.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Travere Announces Agreement with Renalys for Sparsentan in Japan and Southeast Asia

                            Details : Under the agreement, Renalys will bring Filspari (sparsentan), a dual endothelin angiotensin receptor antagonist for the treatment of IgA nephropathy, to patients in Japan and other countries in Asia.

                            Brand Name : Filspari

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 25, 2024

                            Lead Product(s) : Sparsentan

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved

                            Recipient : Travere Therapeutics

                            Deal Size : $120.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Renalys Pharma

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Renalys Pharma

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sparsentan

                            Therapeutic Area : Nephrology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Renalys Pharma Launches Innovative Medicines in Japan and Asia

                            Details : Filspari (sparsentan) is an oral medication targeting key pathways in IgAN disease progression, approved for treating IgA nephropathy.

                            Brand Name : Filspari

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 25, 2024

                            Lead Product(s) : Sparsentan

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth